Risk-based Thinking: The Success of Risk-based Monitoring Begins with Risk-based Thinking

Rick Sax, M.D., Senior Vice President, Integrated Clinical Services, Quintiles

Frederic “Rick” Sax leads Quintiles’ dedicated planning and design unit, the Center for Integrated Drug Development, supporting customer need for clinical program designs. The unit provides design expertise at every step of the drug development spectrum to help partners make knowledge-based decisions about the benefit-risk-value trade-offs of their compounds. Sax also leads Quintiles’ Integrated Clinical Services division, comprised of Cardiac Safety Services, Biostatistics, Medical Writing, Regulatory Affairs and Lifecycle Safety.

Sax joined Quintiles from AstraZeneca’s clinical development leadership team where he served as VP, Clinical Design Strategies. For more than a decade, Sax has led the design of solutions to enhance the quality of program and trial design while driving efficiencies in cost, time and process. Sax’s career spans nearly 20 years in the bioPharmaceutical industry. Prior to joining the industry, he served as an academic cardiologist. Sax graduated with a B.A. in Biology and Philosophy from Yale University, and an M.D. from Columbia University.

Dan White, Vice President, Global Operations, Quintiles

Dan White is Vice President of Global Operations for Quintiles centralized monitoring group (PCC) as well as the endpoint adjudication group (CEVA). In this position, Dan leads over 26 PCC locations around the world including centers in Latin America, Eastern/Western Europe, Australia, South Africa, India, and the US (largest center). Dan is Quintiles subject matter expert on risk-based monitoring, working with sponsors on the implementation of risk-based monitoring across Quintiles organization. Dan has been with Quintiles over 13 years and is based in NC out of the RTP office.